Principal Securities Inc. Purchases 2,555 Shares of Sanofi (NASDAQ:SNY)

Principal Securities Inc. boosted its position in Sanofi (NASDAQ:SNY) by 6.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,050 shares of the company’s stock after buying an additional 2,555 shares during the period. Principal Securities Inc.’s holdings in Sanofi were worth $2,596,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of SNY. Allspring Global Investments Holdings LLC boosted its holdings in shares of Sanofi by 773.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after buying an additional 5,004 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in Sanofi by 5.4% during the first quarter. Sequoia Financial Advisors LLC now owns 19,207 shares of the company’s stock worth $933,000 after acquiring an additional 978 shares in the last quarter. Mission Wealth Management LP grew its holdings in Sanofi by 24.3% in the first quarter. Mission Wealth Management LP now owns 5,185 shares of the company’s stock worth $252,000 after purchasing an additional 1,014 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Sanofi by 7.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,618 shares of the company’s stock worth $2,411,000 after purchasing an additional 3,268 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in shares of Sanofi by 3,440.6% during the first quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock valued at $50,230,000 after purchasing an additional 1,004,358 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.7 %

SNY opened at $53.27 on Friday. The firm has a market capitalization of $135.19 billion, a PE ratio of 27.18, a P/E/G ratio of 1.35 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a fifty-two week low of $45.00 and a fifty-two week high of $58.97. The company’s 50-day moving average is $55.92 and its 200 day moving average is $52.00.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the company earned $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, research analysts predict that Sanofi will post 4.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Sanofi currently has an average rating of “Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.